Table 1.
Association of MIR302-positive ISH with clinical and molecular characteristics in invasive ductal carcinoma (validation TMA cohort)
| Characteristic | MIR302-positive cases, No. (%) (n = 55) | MIR302-negative cases, No. (%) (n = 241) | P |
|---|---|---|---|
| Age, y | .83* | ||
| Median | 48 | 48 | |
| Range | 27–84 | 28–81 | |
| Female sex | 54 (98.2) | 241 (100) | .19† |
| Stage | .03‡ | ||
| I | 4 (7.3) | 39 (16.2) | |
| IIA | 19 (34.5) | 100 (41.5) | |
| IIB | 17 (30.9) | 54 (22.4) | |
| IIIA | 7 (12.7) | 28 (11.6) | |
| IIIB | 3 (5.5) | 16 (6.6) | |
| IIIC | 5 (9.1) | 3 (1.2) | |
| IV | 0 (0) | 1 (0.5) | |
| Grade | .22‡ | ||
| Low | 5 (9.3) | 18 (7.5) | |
| Intermediate | 24 (44.4) | 141 (59.0) | |
| High | 25 (46.3) | 80 (33.5) | |
| N (lymph node) | .005‡ | ||
| 0 | 26 (47.3) | 154 (63.9) | |
| 1 | 13 (23.6) | 52 (21.6) | |
| 2 | 14 (25.5) | 33 (13.7) | |
| 3 | 2 (3.6) | 2 (0.8) | |
| Receptor status | |||
| ER-positive | 9 (20.9) | 44 (28.9) | .44† |
| PR-positive | 10 (23.2) | 33 (21.0) | .83† |
| HER2/neu-positive | 19 (52.8) | 86 (59.3) | .57† |
| Triple-negative§ | 15 (42.1) | 54 (37.6) | .70† |
| P53 positive | 17 (51.5) | 78 (63.9) | .23† |
* Two tailed t test. ER = estrogen receptor; ISH = in situ hybridization; PR = progesterone receptor; TMA = tissue microarray.
† Two-tailed Fisher exact test.
‡ Two-sided Cochran-Armitage test for trend.
§ Cases that are negative for estrogen, progesterone, and HER2/neu receptors.